The Current Therapeutic Landscape for Metastatic Prostate Cancer

Area of Science:

• Oncology
• Translational Medicine
• Cancer Research

Background:

• Prostate cancer (PC) affects over 1.4 million globally in 2024, with standard treatments failing some patients.
• Treatment emergent neuroendocrine prostate cancer (NEPC) is an aggressive subtype with no current approved therapies.
• Limited understanding and treatment options highlight an unmet need for NEPC management.

Purpose of the Study:

• To review current clinical trial regimens for treating late-stage NEPC.
• To identify novel therapeutic targets and combination strategies for NEPC.
• To assess the efficacy of emerging treatments for aggressive prostate cancer.

Main Methods:

• Compilation and analysis of ongoing and completed clinical trials for NEPC.
• Assessment of novel targets including DLL3, EZH2, B7-H3, AURKA, receptor tyrosine kinases, PD-L1, and PD-1.
• Evaluation of treatment outcomes for various therapeutic approaches.

Main Results:

• Alisertib (targeting AURKA) and Cabozantinib (targeting receptor tyrosine kinases) show promising results in NEPC treatment.
• Trials targeting PD-1/PD-L1 immune checkpoints demonstrated limited efficacy.
• Several promising clinical trials are underway, indicating active research in NEPC.

Conclusions:

• The landscape for effective NEPC treatment is currently limited, underscoring the need for novel therapeutic strategies.
• Further research into preventative measures, diagnostics, and biomarkers for NEPC is crucial.
• A deeper clinical understanding of NEPC is essential for improving patient outcomes.